FDA biosimilar review gets faster—but at what safety cost?

What it does

This bill removes one procedural requirement from the FDA's review process for biosimilar drugs—medications designed to copy expensive biologic drugs. It strikes subparagraph (B) of Section 351(k)(5) of the Public Health Service Act and renumbers the remaining provisions. The effect depends entirely on what subparagraph (B) currently requires; without seeing that text, the civic impact cannot be fully assessed, but the bill's stated purpose is to streamline (speed up) FDA approval of biosimilars, which could lower drug costs for patients if it reduces unnecessary delays.

Why we flagged it

The bill's sole function is to remove one procedural step from FDA biosimilar review. Whether this is beneficial or harmful depends on what that step does—a transparency and public-health question, not a market question.

What the text implies

• The bill's civic impact hinges entirely on the content of Section 351(k)(5)(B) of the Public Health Service Act, which is not quoted in this text. If that subparagraph requires comparative clinical efficacy data, its removal could allow biosimilars to reach market with weaker evidence of safety parity. If it is a redundant administrative step, removal is benign.
• Faster biosimilar approvals could reduce drug costs for patients on expensive biologics, but only if the removed requirement was not itself a safeguard against approving inferior or unsafe products.

The full analysis lists 3 implications of this text.

Who stands to gain

biosimilar manufacturers; generic pharmaceutical companies; pharmacy benefit managers (if lower drug costs reduce their costs)